CSIMarket
 
Fate Therapeutics Inc   (NASDAQ: FATE)
 
Price: $2.3800 $-0.01 -0.418%
Day's High: $2.3949999809265137 Week Perf: -7.39 %
Day's Low: $ 2.34 30 Day Perf: -4.8 %
Volume (M): 297,123 52 Wk High: $ 3.23
Volume (M$): $ 0 52 Wk Avg: $1.60
Open: $2.35 52 Wk Low: $0.93



 Market Capitalization (Millions $) 286
 Shares Outstanding (Millions) 120
 Employees 161
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -130
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 5

Business Description


Fate Therapeutics Inc is a biopharmaceutical company that develops advanced cellular therapies that can replace or repair damaged cells in people suffering from severe diseases.
The company is based in San Diego, California, and was founded in 2007.
The company's innovative approach to therapy involves taking cells from a patient's body, engineering them to become specific types of cells, and then reintroducing them into the patient's body, where they can replace or repair damaged cells.
This approach offers a potential solution to many severe diseases, including cancer, genetic disorders, and autoimmune diseases.
Fate Therapeutics Inc's main product is FT516, a treatment designed to replace natural killer cells that work to identify and destroy cancer cells in the body with healthy cells produced outside the body.
They also have other products in development, including FT500, a cancer-killing cell therapy, and FT819, a CAR T-cell therapy for B-cell malignancies.
The company has a strong focus on research and development, and they have partnerships with many leading medical and academic institutions worldwide.
They have also established a strong intellectual property portfolio, which includes over 300 patents and patent applications in the field of cellular therapy.
In summary, Fate Therapeutics Inc is a cutting-edge biopharmaceutical company that develops advanced cellular therapies that can provide a potential cure for many severe diseases.
They have a strong focus on research, development, and intellectual property, making them a leader in the field of cellular therapy.


   Company Address: 12278 Scripps Summit Drive San Diego 92131 CA
   Company Phone Number: 875-1800   Stock Exchange / Ticker: NASDAQ FATE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRA   -6.81%    
GILD   -0.92%    
IMCR   -1.98%    
IOVA   -4.74%    
IPSC   -7.83%    
MRNA   -12.02%    
• View Complete Report
   



Shares

Strategic Talent Inducements at Fate Therapeutics: A Move Toward Future Innovations in Immunotherapy

Published Fri, May 2 2025 8:01 PM UTC

Strategic Talent Acquisition and Equity Allocation at Fate Therapeutics: A Deep Dive into Impact on Shareholders and Market DynamicsIn an era where biotechnology innovation is pivotal, Fate Therapeutics, Inc. (NASDAQ: FATE), a trailblazer in developing induced pluripotent stem cell (iPSC)-derived cellular immunotherapies, has again signaled its commitment to scientific excel...

Product Service News

Off-the-Shelf CAR T-cell Therapy Shows Promise in Treating Systemic Lupus Erythematosus

Published Mon, Dec 9 2024 9:01 PM UTC

In a promising development for autoimmune disease treatment, Fate Therapeutics recently unveiled new Phase 1 clinical trial data for their FT819 CAR T-cell product candidate, designed for patients with systemic lupus erythematosus (SLE). Early results from the trial indicate that the therapy, which is administered in an off-the-shelf format, has demonstrated rapid, deep, and...

Shares

Fate Therapeutics Incentivizes Talent Acquisition with Restricted Stock Units Amid Growing Clinical Ambitions

Published Tue, Dec 3 2024 9:01 PM UTC

Fate Therapeutics Enhances Talent Acquisition Strategy with Restricted Stock Units Amidst Clinical AspirationsOn December 2, 2024, Fate Therapeutics, Inc. (NASDAQ: FATE), a frontrunner in the biopharmaceutical sector focused on pioneering induced pluripotent stem cell (iPSC)-derived cellular immunotherapies, announced the issuance of restricted stock units (RSUs) to a newl...

Clinical Study

Dual Narrative Clinical Triumphs and Financial Challenges at Fate Therapeutics - A New Hope for Lupus Nephritis,

Published Mon, Nov 18 2024 1:05 PM UTC

for CSIMarket.com : A Novel Approach to Lupus Nephritis Treatment Amidst Financial Challenges The field of autoimmune disease treatment is witnessing remarkable advancements, with novel therapies promising improved patient outcomes. Fate Therapeutics, a pioneer in innovative cellular therapeutics, has recently shared promising 6-month follow-up data for its novel off-the-s...

Clinical Study

Advances in Targeted CAR T-cell Therapy Fate Therapeutics’ HER2-Targeting FT825/ONO-8250 and Its Implications for A...

Published Sat, Nov 9 2024 6:30 PM UTC

In the landscape of cancer therapeutics, chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising modality, particularly with its application in hematologic malignancies. However, the adaptation of CAR T-cell therapy for solid tumors has posed multifaceted challenges, primarily due to the heterogeneous expression of tumor-specific antigens and the immunosupp...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 45.23
Price to Sales (Expected) -
Price to Book 1.59
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.7
Working Capital Ratio 5.85
Leverage Ratio (MRQ) 0.17
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.09 $
Revenues (TTM) 0.05 $
Cash Flow (TTM) -
Cash 1.46 $
Book Value 1.5 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 39,230
Net Income per Employee (TTM) -806,876
Receivable Turnover Ratio (TTM) 6.83
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.02

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -2540.42 %
Net Margin (MRQ) -2402.85 %
Net Cash Flow Margin (MRQ) -556.97 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Fate Therapeutics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.